Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-04-22 AGM Information
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2024年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2024 Annual Report. It references the already published 2024 Annual Report (announcement number 2025-018) and invites investors to participate in an online meeting to discuss the report. The document is short (1148 characters) and serves as an announcement for the meeting rather than containing the actual annual report or detailed financial data. Therefore, it fits the category of AGM Information (AGM-R) as it relates to materials shared during an annual meeting or similar event focused on the annual report performance explanation.
2025-04-22 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (auditor) for the year 2024. It discusses the auditor's qualifications, independence, and audit work related to the company's 2024 financial report. It does not contain the actual audited financial statements or detailed financial data but rather an assessment of the auditor's performance and compliance with auditing standards. The document length is 1737 characters, which is relatively short and consistent with an announcement or report on audit performance rather than a full audit report or annual report. Therefore, this document fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit firms' performance, excluding full annual reports. FY 2024
2025-04-22 Chinese
董事会关于独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the company's board regarding the independence of its independent directors. It references compliance with regulatory rules about independent directors and confirms their qualifications and independence. The content is focused on governance and board matters rather than financial results, audit, or shareholder voting. It is not an announcement of a meeting or voting results, nor a certification or legal proceeding. The document is a governance-related report about board members' independence, fitting the category of Board/Management Information (MANG). The document length is short but contains substantive content about board management, not just an announcement or notice.
2025-04-22 Chinese
拟续聘2025年度会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the auditing firm for the fiscal year 2025. It details the auditing firm's background, past service, fees, and the approval process by the board and audit committee. It does not contain any actual audit report, financial statements, or detailed audit results. The document is relatively short (3360 characters) and serves as a formal announcement of the intention to reappoint the auditor, pending shareholder approval. Therefore, it is not an audit report itself but an announcement related to audit services.
2025-04-22 Chinese
2024年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 90% confidence The document is titled as a special explanation regarding non-operating fund occupation and other related party fund transactions by Beijing Northland Biotechnology Co., Ltd., prepared by China Audit Asia Pacific Certified Public Accountants LLP. The content appears to be a detailed audit or special investigation report on specific financial matters related to fund usage and related party transactions. The document length is 2428 characters, which is relatively short but contains substantive content rather than just an announcement. It is not an annual report or interim report, nor is it a general regulatory filing or announcement. The focus on audit and special explanation of financial transactions aligns with the category of Audit Report / Information (AR). There is no indication that this is a certification letter or a report publication announcement. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2025-04-22 Chinese
关于2025年度董事、监事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 100% confidence The document is an announcement regarding the 2025 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards, approval procedures, and committee opinions related to executive compensation. There is no financial data, earnings information, or report publication mentioned. The content focuses specifically on compensation plans for top executives and directors, which aligns with the definition of Remuneration Information filings. The document length is short (1531 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-04-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.